Parexel has launched the Parexel Biotech Incubator, a new initiative anchored at the company’s North Hills Innovation District global headquarters in Raleigh that connects early-stage therapeutics companies with the clinical and regulatory expertise they need to advance their programs. The incubator launches alongside an inaugural partnership with Cape Fear BioCapital, a Durham-based seed-stage venture capital firm, and builds on Parexel’s growing commitment to supporting early-stage innovation in collaboration with the venture community.

The Parexel Biotech Incubator is designed to support emerging therapeutics companies at a stage when development strategy is still taking shape. Participating companies will have access to Parexel’s clinical and regulatory expertise—including guidance on development planning, regulatory strategy and clinical trial design—alongside shared physical space that puts them in direct proximity to Parexel’s Raleigh-based team and provides a collaborative home rather than resources and investment alone.

Peyton Howell, Chief Executive Officer, Parexel, said, “Reaching innovators at the earliest stages of their development journey, before clinical programs are formally structured, is where we can have the greatest impact. That is exactly what this initiative is designed to do. The incubator reflects the evolution of our support for the biotech community, connecting seed-stage investment to clinical development expertise at the stage when it matters most. It builds on our broader commitment to investing in early-stage innovation alongside leading venture firms, and our inaugural partnership with Cape Fear BioCapital deepens our roots in one of the most dynamic life sciences ecosystems in the country.”

The incubator builds on Parexel’s broader commitment to investing in and fostering early-stage innovation alongside leading venture capital firms. Parexel has established collaborative relationships with leading venture firms as part of its strategy to advance and accelerate the next generation of therapeutics companies.

The partnership with Cape Fear BioCapital is designed to address a gap that early-stage therapeutics companies frequently face, where seed-stage investment and clinical development expertise rarely come together at the right time. Cape Fear BioCapital focuses on advancing companies from early discovery through IND-readiness, and the alliance creates a direct connection between its portfolio companies and Parexel’s clinical and regulatory expertise at the stage when development decisions carry the most weight.

Jim Anthony, Chief Commercial Officer and President, Parexel Biotech, said, “The Parexel Biotech Incubator represents the next stage in Parexel Biotech’s evolution and extends our long-standing commitment to the biotech community. By bringing our clinical and regulatory expertise to emerging innovators earlier in their development journeys, we can help companies make smarter development decisions, build stronger plans and position promising programs for lasting progress.”

North Carolina ranks 7th in the US for life sciences employment, with more than 103,000 workers across nearly 6,700 establishments statewide. Anchored by Research Triangle Park, the state is also home to research institutions including Duke University, the University of North Carolina at Chapel Hill and NC State University. Cape Fear BioCapital’s ties to all 3 institutions reinforce the regional research pipeline helping shape North Carolina’s next generation of therapeutics companies.

Dave Ousterout, General Partner, Cape Fear BioCapital, said, “North Carolina has the scientific substrate, talent, and entrepreneurial ambition to build on our strong base of therapeutics innovation. Working together with Parexel, we are dedicated to supporting emerging companies and connecting them with development expertise at a stage when strategic guidance can make a meaningful difference. Our partnership reflects a shared commitment to strengthening the support and capital available to innovators across the state."